Improvement in health-related quality of life in children with ADHD: An analysis of placebo controlled studies of atomoxetine

Amy R. Perwien, Douglas E. Faries, Christopher J. Kratochvil, Calvin R. Sumner, Douglas K. Kelsey, Albert J. Allen

Research output: Contribution to journalArticlepeer-review

82 Scopus citations


Despite significant functional impairments associated with attention-deficit hyperactivity disorder (ADHD) and the growing appreciation of the importance of health-related quality of life (HRQL) assessment in children with chronic disorders, relatively few studies have examined the impact of ADHD treatment on HRQL. This investigation examines the effect of atomoxetine, a nonstimulant treatment for ADHD, on HRQL and identifies factors that are predictive of HRQL improvements. The Child Health Questionnaire (CHQ), which is a multidimensional HRQL measure, was collected during three randomized, double-blind, placebo-controlled clinical trials. Children who received atomoxetine had significantly greater improvement in psychosocial functioning compared to the placebo group. No significant differences between once-a-day and twice-a-day dosing were found. Treatment with atomoxetine, lower HRQL baseline score, no history of stimulant use, and absence of oppositional defiant disorder were all associated with improvements in psychosocial functioning. Findings demonstrate the positive impact of atomoxetine on HRQL in children with ADHD.

Original languageEnglish (US)
Pages (from-to)264-271
Number of pages8
JournalJournal of Developmental and Behavioral Pediatrics
Issue number4
StatePublished - Aug 2004


  • Attention-deficit hyperactivity disorder (ADHD)
  • Clinical trials
  • Health-related quality of life (HRQL)
  • Pharmacological treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental and Educational Psychology
  • Psychiatry and Mental health


Dive into the research topics of 'Improvement in health-related quality of life in children with ADHD: An analysis of placebo controlled studies of atomoxetine'. Together they form a unique fingerprint.

Cite this